Hint mode is switched on Switch off

LB Pharmaceuticals, ordinary share
LBRX, US50180M1080

Add a stock to WL
Choose all Reset all
LB Pharmaceuticals, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad ...
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    LB Pharmaceuticals Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

IFRS/US GAAP reports

2026
I q eng
2025
IV q eng
Show all Hide

Related Stock indices

Indicators

News

13/03/2026 LB Pharmaceuticals: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
04/03/2026 LB Pharmaceuticals: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure, Financial Statements And Exhibits
04/02/2026 LB Pharmaceuticals: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
12/11/2025 LB Pharmaceuticals: Other Events, Financial Statements And Exhibits
10/11/2025 LB Pharmaceuticals: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.